Stem cells, exosomes, gene therapy, peptides, hyperbaric oxygen, and epigenetic reprogramming
589 articles
Young B-cell-derived LTβ reprograms aged periportal hepatocytes, restoring liver regeneration — with an agonist antibody replicating the effect.
GLP-1 receptor agonists are emerging as multi-disease drugs, with new evidence pointing to benefits in liver disease, neurodegeneration, sleep apnea, and addiction.
New research reveals how peak nighttime melatonin triggers mitochondrial cleanup and metabolic shifts that boost blood stem cell regenerative power.
Satellite cells, the stem cells that repair muscle, lose function with age. New single-cell insights reveal why — and how to reverse it.
Advances in large-insert gene editing could transform how we correct disease-causing mutations, with profound implications for age-related and genetic conditions.
What a senescent cell is, how a small population drives systemic inflammation, and an honest account of senolytic human data — early-phase, mechanistic, and short of any outcome a patient cares about.
A deep mechanistic dive into the signaling cascades, epigenetic reprogramming, and translational science behind parabiosis — from GDF11 controversies to clinical plasma trials.
Go beyond the basics of parabiosis to explore the specific proteins, exosomes, and signaling pathways that make young blood rejuvenating — and old blood damaging.
Discover how scientists joined the circulatory systems of young and old mice — and what it taught us about the surprising power of bloodstream factors to reverse signs of aging.
New clinical readouts from the World Conference on Lung Cancer 2026 highlight promising drug developments reshaping lung cancer treatment.
A patient-derived stem cell line carrying a rare DSG2 mutation opens new doors for studying and treating a deadly inherited heart disease.
Scientists are moving beyond gene editing to manipulate entire chromosomes, unlocking new tools for understanding and potentially repairing genetic disease.
